Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over a third of the global population and is linked to serious health problems. A new study has revealed that high blood pressure, diabetes, and low HDL cholesterol are the deadliest cardiometabolic risk factors for patients with MASLD, with high blood pressure proving to be even riskier than diabetes. The findings also show that obesity and body mass index significantly influence mortality, and that each additional risk factor compounds the danger.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over a third of the global population and is linked to serious health problems. A new study has revealed that high blood pressure, diabetes, and low HDL cholesterol are the deadliest cardiometabolic risk factors for patients with MASLD, with high blood pressure proving to be even riskier than diabetes. The findings also show that obesity and body mass index significantly influence mortality, and that each additional risk factor compounds the danger. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over a third of the global population and is linked to serious health problems. A new study has revealed that high blood pressure, diabetes, and low HDL cholesterol are the deadliest cardiometabolic risk factors for patients with MASLD, with high blood pressure proving to be even riskier than diabetes. The findings also show that obesity and body mass index significantly influence mortality, and that each additional risk factor compounds the danger.